Controversial Generic Labeling Rule Put On Back Burner Of FDA's Reg Agenda

A highly contested and yet-to-be-finalized rule on generic drug labeling has been moved from immediate priority to long-term priority on the White House Office of Management and Budget's road map for the year's upcoming regulations. FDA says it considered the White House's executive orders aimed at cutting regulations when developing its list of immediate priorities, known as the Unified Agenda, but emphasized that regulations absent from the immediate priority list could reappear when the agenda is revised in the Fall...